Skip to content

Study · Non-randomized trial · 2008

5 results

Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade.

Sutherland JS, Spyroglou L, Muirhead JL, Heng TS, Prieto-Hinojosa A, Prince HM, Chidgey AP, Schwarer AP, Boyd RL

Clinical cancer research : an official journal of the American Association for Cancer Research1 Feb 2008Cited by 89 (Europe PMC)

PMID18281548 (opens in a new tab)DOI10.1158/1078-0432.ccr-07-1784 (opens in a new tab)PepBankPUB-18281548
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In stem cell transplant patients, goserelin significantly increased neutrophil numbers within the first month after transplantation.

    In plain wordsIn stem cell transplant patients, goserelin increased neutrophil numbers compared with no LHRH-A administration.

    Peptide
    Goserelin
    Outcome
    IncreaseNeutrophil numbers
    Study

    n: not reported in source

    Comparator
    No LHRH-A administration
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 3 weeks before transplantation to 3 months after transplantationAs given in this study (human).

    Source sentences

    Summary
    LHRH-A administration prior to stem cell transplantation significantly increased neutrophil and lymphocyte numbers within the first month of posttransplantation.
    2 context sentences
    Summary · context
    This was a pilot study of luteinizing hormone-releasing hormone agonist (LHRH-A) goserelin given 3 weeks prior to allogeneic or autologous hemopoietic stem cell transplantation and administered up to 3 months posttransplantation.
    Summary · context
    Patients (with or without LHRH-A administration) were assessed from 1 week to 12 months posttransplantation for multiple immunologic variables by flow cytometry (particularly naïve T cells),
  2. 02HumanNon-randomized trialEfficacy outcome

    In stem cell transplant patients, goserelin significantly increased lymphocyte numbers within the first month after transplantation.

    In plain wordsIn stem cell transplant patients, goserelin increased lymphocyte numbers compared with no LHRH-A administration.

    Peptide
    Goserelin
    Outcome
    IncreaseLymphocyte numbers
    Study

    n: not reported in source

    Comparator
    No LHRH-A administration
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 3 weeks before transplantation to 3 months after transplantationAs given in this study (human).

    Source sentences

    Summary
    LHRH-A administration prior to stem cell transplantation significantly increased neutrophil and lymphocyte numbers within the first month of posttransplantation.
    2 context sentences
    Summary · context
    This was a pilot study of luteinizing hormone-releasing hormone agonist (LHRH-A) goserelin given 3 weeks prior to allogeneic or autologous hemopoietic stem cell transplantation and administered up to 3 months posttransplantation.
    Summary · context
    Patients (with or without LHRH-A administration) were assessed from 1 week to 12 months posttransplantation for multiple immunologic variables by flow cytometry (particularly naïve T cells),
  3. 03HumanNon-randomized trialEfficacy outcome

    In stem cell transplant patients, goserelin significantly enhanced total and naïve CD4 T cell regeneration, T-cell receptor excision circle production, repertoire regeneration, and peripheral function.

    In plain wordsIn transplant patients, goserelin enhanced T cell regeneration, thymus-related measures, repertoire regeneration, and function compared with no LHRH-A administration.

    Peptide
    Goserelin
    Outcome
    IncreaseT cell regeneration and function
    Study

    n: not reported in source

    Comparator
    No LHRH-A administration
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated · 3 weeks before transplantation to 3 months after transplantationAs given in this study (human).

    Source sentences

    Summary
    Most importantly, total and naïve CD4(+) T cell regeneration together with T-cell receptor excision circle production, T cell repertoire regeneration, and peripheral T cell function were also significantly enhanced at multiple time points posttransplant.
    2 context sentences
    Summary · context
    This was a pilot study of luteinizing hormone-releasing hormone agonist (LHRH-A) goserelin given 3 weeks prior to allogeneic or autologous hemopoietic stem cell transplantation and administered up to 3 months posttransplantation.
    Summary · context
    Patients (with or without LHRH-A administration) were assessed from 1 week to 12 months posttransplantation for multiple immunologic variables by flow cytometry (particularly naïve T cells),
  4. 04HumanNon-randomized trialEfficacy outcome

    In autologous stem cell transplant patients, an increase in disease-free survival was seen with goserelin (P = 0.04).

    In plain wordsIn autologous stem cell transplant patients, disease-free survival was higher with goserelin than without LHRH-A.

    Peptide
    Goserelin
    Outcome
    IncreaseDisease-free survival after autologous transplantation
    Study

    n: not reported in source

    Comparator
    No LHRH-A administration
    Outcome group
    Cancer Survival · Cancer
    Studied dose
    Dose not stated · 3 weeks before transplantation to 3 months after transplantationAs given in this study (human).

    Measurements

    P value
    0.04 unitless
    disease-free survival, autologous setting, goserelin vs no LHRH-A

    Source sentences

    Summary
    In addition, an increase in disease-free survival (P = 0.04) was seen in the autologous setting.
    2 context sentences
    Summary · context
    This was a pilot study of luteinizing hormone-releasing hormone agonist (LHRH-A) goserelin given 3 weeks prior to allogeneic or autologous hemopoietic stem cell transplantation and administered up to 3 months posttransplantation.
    Summary · context
    Patients (with or without LHRH-A administration) were assessed from 1 week to 12 months posttransplantation for multiple immunologic variables by flow cytometry (particularly naïve T cells),
  5. 05HumanNon-randomized trialSafety outcome

    In allogeneic stem cell transplant patients, goserelin did not exacerbate graft-versus-host disease.

    In plain wordsIn allogeneic stem cell transplant patients, goserelin did not worsen graft-versus-host disease compared with no LHRH-A administration.

    Peptide
    Goserelin
    Outcome
    No significant changeGraft-versus-host disease
    Study

    n: not reported in source

    Comparator
    No LHRH-A administration
    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated · 3 weeks before transplantation to 3 months after transplantationAs given in this study (human).

    Source sentences

    Summary
    Although LHRH-A administration increased T cell responses in vitro, it did not exacerbate graft-versus-host disease in the allogeneic setting.
    2 context sentences
    Summary · context
    This was a pilot study of luteinizing hormone-releasing hormone agonist (LHRH-A) goserelin given 3 weeks prior to allogeneic or autologous hemopoietic stem cell transplantation and administered up to 3 months posttransplantation.
    Summary · context
    Patients (with or without LHRH-A administration) were assessed from 1 week to 12 months posttransplantation for multiple immunologic variables by flow cytometry (particularly naïve T cells),

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.